Events And

EASL International Liver Congress™ 2024

Jun 05, 2024 at 8:30 AM CEST

Title: Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model
(abstract #2881)

Speaker: Sarah Browne, M.D., Vice President, Clinical Development, Altimmune


Title: Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis
(abstract #2985)

Speaker: Scot Roberts, Ph.D., Chief Scientific Officer, Altimmune


Title: Pemvidutide treatment is associated with improvement in noninvasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial
(abstract #3002)

Speaker: Shaheen Tomah, M.D., Associate Director, Clinical Development, Altimmune


Milan, Italy

Investor Contact


Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail